{
  "aggregate": {
    "max_possible_score": 14,
    "percent_score": 42.9,
    "star_display": "★★",
    "star_rating": 2,
    "total_score": 6
  },
  "company": "Danaher",
  "company_slug": "danaher",
  "evidence_breakdown": {
    "by_type": {
      "NARRATIVE": 14,
      "OPERATIONAL": 2,
      "POLICY": 18
    }
  },
  "pillar_scores": {
    "explainability": {
      "best_evidence_type": "POLICY",
      "display_name": "Explainability",
      "evidence_count": 2,
      "findings": "Company blog posts state aims for explainability in AI systems. These posts also discuss the importance of transparent, interpretable AI models, particularly deep learning, in drug discovery.",
      "max_score": 2,
      "path_to_improvement": "Publish user-facing explanation interfaces or documented appeal workflows.",
      "relevant_sources": [
        {
          "artifact_type": "blog_post",
          "source_id": "src_007",
          "source_tier": "company_owned",
          "summary": "This company-owned blog post, \"AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance,\" provides evidence for the **privacy**, **governance**, **transparency**, and **explainability** pillars. It supports the privacy pillar by highlighting data protection concerns and legal compliance requirements for AI model training. The blog post touches on governance by mentioning AI tools for regulatory analysis and risk detection, and implies governance through the discussion of diverse AI applications and data integration for decision-making. Transparency is supported by descriptions of AI capabilities and use cases in pharma research, as well as mentions of AI tools and their predictive capabilities. Finally, the source aligns with explainability by stating aims for explainability in AI systems.",
          "title": "AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance",
          "url": "https://lifesciences.danaher.com/us/en/library/ai-in-pharmaceutical-industry.html"
        },
        {
          "artifact_type": "blog_post",
          "source_id": "src_008",
          "source_tier": "company_owned",
          "summary": "This company-owned blog post provides evidence for **explainability**, **governance**, and **transparency** by discussing the importance of transparent, interpretable AI models, particularly deep learning, in drug discovery. The post advocates for detailed documentation and adherence to data governance policies to ensure legal compliance and regulatory standards, thereby supporting the governance pillar. Furthermore, it details various AI/ML capabilities and techniques, contributing to transparency about AI system functions and capabilities.",
          "title": "AI in Drug Discovery and Development - Regulatory and Ethical Considerations",
          "url": "https://lifesciences.danaher.com/us/en/library/artificial-intelligence-in-drug-discovery.html"
        }
      ],
      "score": 1,
      "source_count": 2
    },
    "external_accountability": {
      "best_evidence_type": null,
      "display_name": "Public Commitments & External Audits",
      "evidence_count": 0,
      "findings": null,
      "max_score": 2,
      "path_to_improvement": "Obtain external validation of AI practices or require vendor certifications.",
      "relevant_sources": [],
      "score": 0,
      "source_count": 0
    },
    "fairness": {
      "best_evidence_type": "POLICY",
      "display_name": "Fairness & Bias Mitigation",
      "evidence_count": 1,
      "findings": "Sources describe documented fairness practices in 1 source(s). Additional documentation references related practices.",
      "max_score": 2,
      "path_to_improvement": "Publish bias testing results, outcome monitoring, or vendor fairness certifications.",
      "relevant_sources": [
        {
          "artifact_type": "blog_post",
          "source_id": "src_007",
          "source_tier": "company_owned",
          "summary": "This company-owned blog post, \"AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance,\" provides evidence for the **privacy**, **governance**, **transparency**, and **explainability** pillars. It supports the privacy pillar by highlighting data protection concerns and legal compliance requirements for AI model training. The blog post touches on governance by mentioning AI tools for regulatory analysis and risk detection, and implies governance through the discussion of diverse AI applications and data integration for decision-making. Transparency is supported by descriptions of AI capabilities and use cases in pharma research, as well as mentions of AI tools and their predictive capabilities. Finally, the source aligns with explainability by stating aims for explainability in AI systems.",
          "title": "AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance",
          "url": "https://lifesciences.danaher.com/us/en/library/ai-in-pharmaceutical-industry.html"
        }
      ],
      "score": 1,
      "source_count": 1
    },
    "governance": {
      "best_evidence_type": "OPERATIONAL",
      "display_name": "Governance & Accountability",
      "evidence_count": 19,
      "findings": "The company outlines a commitment to data quality and utility for AI, focusing on impactful applications and describing a deliberate process for selecting AI solutions. Governance is further supported by a formal leadership structure, including a Chief Technology and AI Officer, and board-level oversight of innovation strategy. Additionally, the company describes an open architecture platform with integration controls for third-party algorithms, mentions AI tools for regulatory analysis, and advocates for detailed documentation and adherence to data governance policies.",
      "max_score": 2,
      "path_to_improvement": null,
      "relevant_sources": [
        {
          "artifact_type": "help_page",
          "source_id": "src_001",
          "source_tier": "company_owned",
          "summary": "This company-owned help page, Danaher's \"Artificial Intelligence Strategy Page,\" provides evidence for the **governance** pillar of responsible AI. The document outlines a commitment to data quality and utility for AI, and a focus on ensuring AI-enabled creations address real-world healthcare challenges and have a tangible impact. It also describes a deliberate process for selecting appropriate AI applications, indicating strategic direction and purposeful AI deployment.",
          "title": "Artificial Intelligence Strategy Page",
          "url": "https://danaher.com/artificial-intelligence"
        },
        {
          "artifact_type": "proxy_statement",
          "source_id": "src_002",
          "source_tier": "third_party",
          "summary": "The Danaher 2025 Proxy Statement provides evidence for the **governance** pillar of responsible AI. This proxy statement supports governance by detailing the company's board composition and committee structure, specifically highlighting the Science & Technology Committee's oversight of innovation strategy and disruptive technology assessment. Furthermore, the addition of an AI expert to the board and the inclusion of leading AI integration as a qualitative executive compensation goal demonstrate a commitment to AI governance and strategic direction.",
          "title": "Danaher 2025 Proxy Statement",
          "url": "https://filecache.investorroom.com/mr5ir_danaher/919/download/Danaher%202025%20Proxy%20Statement.pdf"
        },
        {
          "artifact_type": "press_release",
          "source_id": "src_004",
          "source_tier": "company_owned",
          "summary": "This press release provides evidence for the **governance** pillar of responsible AI. The announcement of a Chief Technology and AI Officer, reporting directly to the CEO, signifies a formal leadership structure and commitment to AI integration. Furthermore, the mention of the appointee's past experience in founding Google Cancer Pathology and leading AI initiatives at Tempus indicates a history of driving AI strategy and execution, supporting the governance pillar by demonstrating established practices and future intent.",
          "title": "Danaher Appoints Martin Stumpe as Chief Technology and AI Officer",
          "url": "https://investors.danaher.com/2025-06-27-Danaher-Appoints-Martin-Stumpe-as-Chief-Technology-and-AI-Officer"
        },
        {
          "artifact_type": "blog_post",
          "source_id": "src_005",
          "source_tier": "company_owned",
          "summary": "This company blog post, an interview with Danaher's Chief Data and AI Officer, provides evidence for the **governance** and **transparency** pillars of responsible AI. The source discusses a strategic governance perspective on AI integration and organizational readiness, as well as AI's role in molecule design with a need for validation, implying governance over AI feedback loops. Transparency is supported by descriptions of specific AI use cases like computer vision and multimodal AI for user insights, and AI applications for productivity such as information retrieval and content creation.",
          "title": "Meet Danaher's Chief Data and AI Officer",
          "url": "https://jobsblog.danaher.com/blog/meet-danahers-chief-data-and-ai-officer"
        },
        {
          "artifact_type": "press_release",
          "source_id": "src_006",
          "source_tier": "third_party",
          "summary": "This press release provides evidence for the **governance** and **transparency** pillars of responsible AI. It supports governance by describing an open architecture platform that enables pharmaceutical partners to develop and deploy third-party algorithms with integration controls, implying oversight of algorithm development and use. Transparency is supported through the mention of an AI-powered solution, vendor collaboration, and the provision of access to AI solutions, indicating openness about the AI's capabilities and partnerships.",
          "title": "Leica Biosystems Aperio HALO AP and Aperio AI Store Launch",
          "url": "https://www.leicabiosystems.com/us/news/leica-biosystems-expands-leading-digital-pathology-portfolio-for-us-multiple-launches-at-pathology-visions-2025/"
        },
        {
          "artifact_type": "blog_post",
          "source_id": "src_007",
          "source_tier": "company_owned",
          "summary": "This company-owned blog post, \"AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance,\" provides evidence for the **privacy**, **governance**, **transparency**, and **explainability** pillars. It supports the privacy pillar by highlighting data protection concerns and legal compliance requirements for AI model training. The blog post touches on governance by mentioning AI tools for regulatory analysis and risk detection, and implies governance through the discussion of diverse AI applications and data integration for decision-making. Transparency is supported by descriptions of AI capabilities and use cases in pharma research, as well as mentions of AI tools and their predictive capabilities. Finally, the source aligns with explainability by stating aims for explainability in AI systems.",
          "title": "AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance",
          "url": "https://lifesciences.danaher.com/us/en/library/ai-in-pharmaceutical-industry.html"
        },
        {
          "artifact_type": "blog_post",
          "source_id": "src_008",
          "source_tier": "company_owned",
          "summary": "This company-owned blog post provides evidence for **explainability**, **governance**, and **transparency** by discussing the importance of transparent, interpretable AI models, particularly deep learning, in drug discovery. The post advocates for detailed documentation and adherence to data governance policies to ensure legal compliance and regulatory standards, thereby supporting the governance pillar. Furthermore, it details various AI/ML capabilities and techniques, contributing to transparency about AI system functions and capabilities.",
          "title": "AI in Drug Discovery and Development - Regulatory and Ethical Considerations",
          "url": "https://lifesciences.danaher.com/us/en/library/artificial-intelligence-in-drug-discovery.html"
        }
      ],
      "score": 2,
      "source_count": 7
    },
    "oversight": {
      "best_evidence_type": null,
      "display_name": "Human Oversight & Accountability",
      "evidence_count": 0,
      "findings": null,
      "max_score": 2,
      "path_to_improvement": "Document human review processes for AI-assisted decisions (built or vendor AI).",
      "relevant_sources": [],
      "score": 0,
      "source_count": 0
    },
    "privacy": {
      "best_evidence_type": "POLICY",
      "display_name": "Privacy & Security",
      "evidence_count": 1,
      "findings": "Company blog posts highlight data protection concerns for AI model training. These posts also highlight legal compliance requirements for AI model training.",
      "max_score": 2,
      "path_to_improvement": "Publish AI-specific privacy impact assessments or data handling procedures.",
      "relevant_sources": [
        {
          "artifact_type": "blog_post",
          "source_id": "src_007",
          "source_tier": "company_owned",
          "summary": "This company-owned blog post, \"AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance,\" provides evidence for the **privacy**, **governance**, **transparency**, and **explainability** pillars. It supports the privacy pillar by highlighting data protection concerns and legal compliance requirements for AI model training. The blog post touches on governance by mentioning AI tools for regulatory analysis and risk detection, and implies governance through the discussion of diverse AI applications and data integration for decision-making. Transparency is supported by descriptions of AI capabilities and use cases in pharma research, as well as mentions of AI tools and their predictive capabilities. Finally, the source aligns with explainability by stating aims for explainability in AI systems.",
          "title": "AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance",
          "url": "https://lifesciences.danaher.com/us/en/library/ai-in-pharmaceutical-industry.html"
        }
      ],
      "score": 1,
      "source_count": 1
    },
    "transparency": {
      "best_evidence_type": "POLICY",
      "display_name": "Transparency",
      "evidence_count": 17,
      "findings": "Company blog posts describe specific AI use cases, including computer vision, multimodal AI for user insights, information retrieval, content creation, and applications in pharmaceutical research. These posts also detail various AI/ML capabilities, techniques, and predictive tools, contributing to transparency about AI system functions. Additionally, a press release mentions an AI-powered solution, vendor collaboration, and access to AI solutions, indicating openness about AI capabilities and partnerships.",
      "max_score": 2,
      "path_to_improvement": "Publish detailed documentation (model cards, system specs) for AI systems deployed.",
      "relevant_sources": [
        {
          "artifact_type": "blog_post",
          "source_id": "src_005",
          "source_tier": "company_owned",
          "summary": "This company blog post, an interview with Danaher's Chief Data and AI Officer, provides evidence for the **governance** and **transparency** pillars of responsible AI. The source discusses a strategic governance perspective on AI integration and organizational readiness, as well as AI's role in molecule design with a need for validation, implying governance over AI feedback loops. Transparency is supported by descriptions of specific AI use cases like computer vision and multimodal AI for user insights, and AI applications for productivity such as information retrieval and content creation.",
          "title": "Meet Danaher's Chief Data and AI Officer",
          "url": "https://jobsblog.danaher.com/blog/meet-danahers-chief-data-and-ai-officer"
        },
        {
          "artifact_type": "press_release",
          "source_id": "src_006",
          "source_tier": "third_party",
          "summary": "This press release provides evidence for the **governance** and **transparency** pillars of responsible AI. It supports governance by describing an open architecture platform that enables pharmaceutical partners to develop and deploy third-party algorithms with integration controls, implying oversight of algorithm development and use. Transparency is supported through the mention of an AI-powered solution, vendor collaboration, and the provision of access to AI solutions, indicating openness about the AI's capabilities and partnerships.",
          "title": "Leica Biosystems Aperio HALO AP and Aperio AI Store Launch",
          "url": "https://www.leicabiosystems.com/us/news/leica-biosystems-expands-leading-digital-pathology-portfolio-for-us-multiple-launches-at-pathology-visions-2025/"
        },
        {
          "artifact_type": "blog_post",
          "source_id": "src_007",
          "source_tier": "company_owned",
          "summary": "This company-owned blog post, \"AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance,\" provides evidence for the **privacy**, **governance**, **transparency**, and **explainability** pillars. It supports the privacy pillar by highlighting data protection concerns and legal compliance requirements for AI model training. The blog post touches on governance by mentioning AI tools for regulatory analysis and risk detection, and implies governance through the discussion of diverse AI applications and data integration for decision-making. Transparency is supported by descriptions of AI capabilities and use cases in pharma research, as well as mentions of AI tools and their predictive capabilities. Finally, the source aligns with explainability by stating aims for explainability in AI systems.",
          "title": "AI in Pharmaceutical Industry - Data Privacy and Regulatory Compliance",
          "url": "https://lifesciences.danaher.com/us/en/library/ai-in-pharmaceutical-industry.html"
        },
        {
          "artifact_type": "blog_post",
          "source_id": "src_008",
          "source_tier": "company_owned",
          "summary": "This company-owned blog post provides evidence for **explainability**, **governance**, and **transparency** by discussing the importance of transparent, interpretable AI models, particularly deep learning, in drug discovery. The post advocates for detailed documentation and adherence to data governance policies to ensure legal compliance and regulatory standards, thereby supporting the governance pillar. Furthermore, it details various AI/ML capabilities and techniques, contributing to transparency about AI system functions and capabilities.",
          "title": "AI in Drug Discovery and Development - Regulatory and Ethical Considerations",
          "url": "https://lifesciences.danaher.com/us/en/library/artificial-intelligence-in-drug-discovery.html"
        }
      ],
      "score": 1,
      "source_count": 4
    }
  },
  "published_at": "2026-02-23T21:48:19Z",
  "run_id": "20260202_221552_5103",
  "schema_version": "1.0",
  "summary": {
    "key_gaps": [
      "Human Oversight & Accountability",
      "Public Commitments & External Audits"
    ],
    "key_strengths": [
      "Governance & Accountability"
    ],
    "overall_findings": "Danaher's published materials outline a commitment to data quality and utility for AI, addressing governance at an operational level. This is one of five responsible AI pillars with documented evidence, with transparency, fairness, explainability, and privacy addressed through corporate policies. For instance, company blog posts describe specific AI use cases, including computer vision and multimodal AI for user insights, while also highlighting data protection concerns for AI model training. Further disclosures discuss the importance of transparent, interpretable AI models in drug discovery and describe documented fairness practices. No qualifying public evidence was found for oversight or external accountability. This assessment draws on 9 publicly available sources.",
    "pillars_operational": 1,
    "pillars_policy_only": 4,
    "pillars_with_evidence": 5,
    "pillars_without_evidence": 2,
    "total_evidence_items": 34,
    "total_sources_used": 7
  }
}
